Equibles does not estimate personal net worth.
Get an email with a short summary when C4 Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CCCC alertsThe proxy statement of C4 Therapeutics, Inc. reports total compensation of $3,914,000 for Scott N. Boyle in fiscal 2022, including a base salary of $398,718. Scott N. Boyle has spoken on 2 investor events across 1 company, most recently for C4 Therapeutics, Inc. on September 10, 2026. C4 Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at C4 Therapeutics, Inc. includes Andrew J. Hirsch (CEO), Andrew Phillips (CEO), Ron Cooper (Chairman and Board Member) and 7 others.
“You know, I think we can say we're making progress and there are discovery milestones in some of the collaborations that would be, you know, communicable events for us.”
“Sure yeah so Like Andrew said, we believe that the immune agents are going to move earlier, creating a larger fourth-line opportunity. The Momentum study is intending to tackle that fourth-line patient population.”
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | $398,718 | $3,914,000 |
